PL2838892T3 - Wyodrębniona stała postać monochlorowodorku anamoreliny z niskim stosunkiem molowym chlorek:anamorelina i niską zawartością resztkowego rozpuszczalnika organicznego - Google Patents

Wyodrębniona stała postać monochlorowodorku anamoreliny z niskim stosunkiem molowym chlorek:anamorelina i niską zawartością resztkowego rozpuszczalnika organicznego

Info

Publication number
PL2838892T3
PL2838892T3 PL13719344T PL13719344T PL2838892T3 PL 2838892 T3 PL2838892 T3 PL 2838892T3 PL 13719344 T PL13719344 T PL 13719344T PL 13719344 T PL13719344 T PL 13719344T PL 2838892 T3 PL2838892 T3 PL 2838892T3
Authority
PL
Poland
Prior art keywords
low
anamolerin
chloride
organic solvent
molar ratio
Prior art date
Application number
PL13719344T
Other languages
English (en)
Polish (pl)
Inventor
Shin-Itsu Kuwabe
Takehiko YANAGIMACHI
Hideyuki YOSHIYAMA
Eleanor DE GROOT
Silvina Garcia Rubio
Peter Manini
Seemon Pines
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48225135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2838892(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of PL2838892T3 publication Critical patent/PL2838892T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
PL13719344T 2012-04-20 2013-04-18 Wyodrębniona stała postać monochlorowodorku anamoreliny z niskim stosunkiem molowym chlorek:anamorelina i niską zawartością resztkowego rozpuszczalnika organicznego PL2838892T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261636108P 2012-04-20 2012-04-20
PCT/US2013/037159 WO2013158874A1 (fr) 2012-04-20 2013-04-18 Procédés de production de chlorhydrate d'anamoréline présentant une teneur en chlorure régulée
EP13719344.7A EP2838892B1 (fr) 2012-04-20 2013-04-18 Forme solide isolée de monohdydrochloride d'anamorelin avec un rapport molar chloride:anamorelin bas et un contenu de solvants organiques residuels bas

Publications (1)

Publication Number Publication Date
PL2838892T3 true PL2838892T3 (pl) 2018-05-30

Family

ID=48225135

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17192651T PL3290410T3 (pl) 2012-04-20 2013-04-18 Wyodrębniona stała postać monochlorowodorku anamoreliny o niskim stosunku molowym chlorek : anamorelina
PL13719344T PL2838892T3 (pl) 2012-04-20 2013-04-18 Wyodrębniona stała postać monochlorowodorku anamoreliny z niskim stosunkiem molowym chlorek:anamorelina i niską zawartością resztkowego rozpuszczalnika organicznego

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL17192651T PL3290410T3 (pl) 2012-04-20 2013-04-18 Wyodrębniona stała postać monochlorowodorku anamoreliny o niskim stosunku molowym chlorek : anamorelina

Country Status (47)

Country Link
US (8) US20140018391A1 (fr)
EP (3) EP3290410B1 (fr)
JP (3) JP6109925B2 (fr)
KR (2) KR102141323B1 (fr)
CN (3) CN103857669B (fr)
AP (1) AP2014008013A0 (fr)
AR (1) AR090725A1 (fr)
AU (1) AU2013249197B2 (fr)
BR (1) BR112014025972A8 (fr)
CA (2) CA2869893C (fr)
CL (1) CL2014002817A1 (fr)
CO (1) CO7131356A2 (fr)
CR (1) CR20140530A (fr)
CY (1) CY1120276T1 (fr)
DK (2) DK3517532T3 (fr)
DO (1) DOP2014000235A (fr)
EA (1) EA031581B1 (fr)
EC (1) ECSP14027739A (fr)
ES (2) ES2820354T3 (fr)
GE (1) GEP20186902B (fr)
HK (2) HK1202863A1 (fr)
HR (1) HRP20180316T1 (fr)
HU (2) HUE035697T2 (fr)
IL (1) IL235064B (fr)
JO (1) JO3353B1 (fr)
LT (1) LT2838892T (fr)
MA (1) MA37524B1 (fr)
MD (1) MD4615C1 (fr)
ME (1) ME02966B (fr)
MX (1) MX354793B (fr)
MY (1) MY170068A (fr)
NI (1) NI201400124A (fr)
NO (1) NO2877697T3 (fr)
NZ (1) NZ700833A (fr)
PE (1) PE20150084A1 (fr)
PH (1) PH12014502351A1 (fr)
PL (2) PL3290410T3 (fr)
PT (2) PT2838892T (fr)
RS (1) RS56869B1 (fr)
SG (2) SG10201608488RA (fr)
SI (2) SI2838892T1 (fr)
TN (1) TN2014000421A1 (fr)
TW (2) TWI589572B (fr)
UA (1) UA116207C2 (fr)
UY (1) UY34753A (fr)
WO (1) WO2013158874A1 (fr)
ZA (1) ZA201408508B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
AP2017009772A0 (en) * 2014-09-04 2017-02-28 Helsinn Healthcare Sa Medical treatments based on anamorelin
MA43294A1 (fr) 2015-07-24 2020-04-30 Newlink Genetics Corp Sels et promédicaments de 1-méthyl -d-tryptophane
CN108239141A (zh) * 2016-12-23 2018-07-03 江苏先声药业有限公司 一种阿拉莫林的制备方法
US20220323430A1 (en) * 2019-08-30 2022-10-13 Helsinn Healthcare Sa Methods of manufacturing anamorelin tablets having improved stability

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73530C2 (uk) * 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
CN1882526A (zh) * 2003-09-26 2006-12-20 兰贝克赛实验室有限公司 制备伏格列波糖的方法
EP1768976B1 (fr) 2004-06-29 2017-04-26 Helsinn Healthcare S.A. Formes cristallines d'acide (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylique 1,2,2-trimethylhydrazide
WO2008100448A2 (fr) 2007-02-13 2008-08-21 Helsinn Therapeutics (U.S.), Inc. Procédé de traitement des troubles prolifératifs cellulaires utilisant un sécrétagogue d'hormone de croissance
UA105657C2 (uk) 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي

Also Published As

Publication number Publication date
UY34753A (es) 2013-11-29
ES2820354T3 (es) 2021-04-20
EP3517532A1 (fr) 2019-07-31
HK1202863A1 (en) 2015-10-09
PE20150084A1 (es) 2015-01-23
SG11201406478XA (en) 2014-11-27
MD20140122A2 (ro) 2015-05-31
TN2014000421A1 (en) 2016-03-30
JO3353B1 (ar) 2019-03-13
PT3517532T (pt) 2021-11-08
GEP20186902B (en) 2018-10-25
NZ700833A (en) 2016-01-29
CN110041398A (zh) 2019-07-23
ECSP14027739A (es) 2015-12-31
BR112014025972A8 (pt) 2021-06-22
LT2838892T (lt) 2018-03-12
SG10201608488RA (en) 2016-12-29
US20190000914A1 (en) 2019-01-03
US10576122B2 (en) 2020-03-03
CN103857669B (zh) 2019-06-28
EP3517532B1 (fr) 2021-10-13
HUE035697T2 (en) 2018-05-28
PT2838892T (pt) 2018-02-28
BR112014025972A2 (pt) 2017-06-27
US9403867B2 (en) 2016-08-02
US20190231843A1 (en) 2019-08-01
PL3290410T3 (pl) 2021-01-11
AP2014008013A0 (en) 2014-10-31
CA2869893C (fr) 2019-03-05
CN110041304A (zh) 2019-07-23
CA3031652A1 (fr) 2013-10-24
US9981002B2 (en) 2018-05-29
ME02966B (fr) 2018-07-20
NO2877697T3 (fr) 2018-10-13
CA2869893A1 (fr) 2013-10-24
US10300105B2 (en) 2019-05-28
US9872883B2 (en) 2018-01-23
NI201400124A (es) 2015-09-21
EP2838892B1 (fr) 2017-12-06
TWI589572B (zh) 2017-07-01
AR090725A1 (es) 2014-12-03
JP6616853B2 (ja) 2019-12-04
CR20140530A (es) 2015-03-25
UA116207C2 (uk) 2018-02-26
RS56869B1 (sr) 2018-04-30
IL235064A0 (en) 2014-12-31
US20200276259A1 (en) 2020-09-03
WO2013158874A1 (fr) 2013-10-24
EP3290410A1 (fr) 2018-03-07
US20160237115A1 (en) 2016-08-18
AU2013249197A1 (en) 2014-10-30
US20150072934A1 (en) 2015-03-12
AU2013249197B2 (en) 2017-04-06
KR20150013115A (ko) 2015-02-04
CA3031652C (fr) 2020-10-27
JP2015514779A (ja) 2015-05-21
MY170068A (en) 2019-07-03
US20160229889A1 (en) 2016-08-11
SI2838892T1 (en) 2018-05-31
EA201401151A1 (ru) 2015-06-30
HUE050865T2 (hu) 2021-01-28
PH12014502351B1 (en) 2015-01-12
ES2658862T3 (es) 2018-03-12
KR102141323B1 (ko) 2020-08-05
DK2838892T3 (en) 2018-03-12
JP2017101082A (ja) 2017-06-08
KR101972998B1 (ko) 2019-04-29
HRP20180316T1 (hr) 2018-04-06
TWI677494B (zh) 2019-11-21
HK1248694A1 (zh) 2018-10-19
MX2014012178A (es) 2015-08-05
SI3290410T1 (sl) 2020-11-30
EP2838892A1 (fr) 2015-02-25
US10905737B2 (en) 2021-02-02
MX354793B (es) 2018-03-21
DK3517532T3 (da) 2022-01-03
US9956261B2 (en) 2018-05-01
MD4615C1 (ro) 2019-08-31
US20160235804A1 (en) 2016-08-18
PH12014502351A1 (en) 2015-01-12
KR20190044697A (ko) 2019-04-30
CO7131356A2 (es) 2014-12-01
CN103857669A (zh) 2014-06-11
EP3290410B1 (fr) 2020-07-01
CY1120276T1 (el) 2019-07-10
MD4615B1 (ro) 2019-01-31
ZA201408508B (en) 2020-01-29
MA37524B1 (fr) 2017-04-28
JP6284665B2 (ja) 2018-02-28
IL235064B (en) 2019-09-26
TW201722928A (zh) 2017-07-01
DOP2014000235A (es) 2015-01-31
TW201348224A (zh) 2013-12-01
MA37524A1 (fr) 2016-06-30
US20140018391A1 (en) 2014-01-16
JP2018076375A (ja) 2018-05-17
JP6109925B2 (ja) 2017-04-05
EA031581B1 (ru) 2019-01-31
CL2014002817A1 (es) 2015-08-14

Similar Documents

Publication Publication Date Title
HK1201355A1 (en) Vector string range compare
HK1213016A1 (zh) 細胞調節化合物及其用途
HK1214259A1 (zh) 衍生物
HK1207069A1 (en) Heterocyclic compounds and uses thereof
HK1208439A1 (en) 5-azaindazole compounds and methods of use 5-
EP2818464A4 (fr) Nouveau composé organique contenant du chalcogène et son utilisation
HK1199023A1 (en) Substituted benzothienylpyrrolotriazines and uses thereof
EP2885715A4 (fr) Partage de contenu avec des dispositifs proches
IL237309A0 (en) Benzocyclooctyne compounds and uses thereof
HK1200822A1 (en) Substituted dipyridylamines and uses thereof
PL2920149T3 (pl) Związki 3-aminocykloalkilowe jako inhibitory ror-gamma-t oraz ich zastosowania
EP2847254A4 (fr) Modification chimique de lignine et de dérivés de lignine
EP2886546A4 (fr) Composé hétérocyclique et son utilisation
EP2847255A4 (fr) Modification chimique de lignine et de dérivés de lignine
AP3611A (en) Heterocyclic compounds and their uses
SG11201406529UA (en) Storage and stabilization of acetylene
HK1201270A1 (en) Tetrazol-5-yl- and triazol-5-yl-aryl compounds and use thereof as herbicides -5---5--
ME02966B (fr) Forme solide isolée de monohdydrochloride d'anamorelin avec un rapport molar chloride:anamorelin bas et un contenu de solvants organiques residuels bas
GB2486025B (en) Content searching
EP2928385A4 (fr) Ancrages de poignée tournante et procédés d'utilisation
PL2882708T3 (pl) Nowe związki i ich zastosowania
EP2813508A4 (fr) Composé hétérocyclique et application associée
GB2503216B (en) Continuity of content
GB201222342D0 (en) Compounds and uses thereof
GB201215716D0 (en) Palletising of composted organic matter